Marcello Moccia

Jan 20, 2025 | neurologylive.com | Marcello Moccia |Isabella Ciccone

WATCH TIME: 4 minutes"A huge update is that we are moving from a clinical diagnosis to the diagnosis of a biological disease."Despite ongoing advancements in the therapeutic landscape, the impact of different disease-modifying treatment (DMT) sequences on healthcare system burden in multiple sclerosis (MS) remains underexplored.

Oct 6, 2024 | neurologylive.com | Marcello Moccia |Isabella Ciccone

WATCH TIME: 4 minutes"Each MS unit should combine the different tools they have ease to access to make the diagnosis of MS.

Sep 11, 2023 | journals.sagepub.com | Marcello Moccia |Maria amato |Peter A Calabresi

Introduction Since the publication of the Lublin–Reingold clinical course descriptors for multiple sclerosis (MS) in 1996, and the revised descriptors in 2013, there have been calls for the development of course descriptors anchored to the biological mechanisms of the disease.1 Some conceptual models have been suggested, but as yet none have been widely adopted (Antel, Antel and Caramanos, 2012).2,3,4 Recently, the International Advisory Committee on Clinical Trials in Multiple Sclerosis (an...

Sep 11, 2023 | journals.sagepub.com | Marcello Moccia |Maria amato |Peter A Calabresi

Introduction Since the publication of the Lublin–Reingold clinical course descriptors for multiple sclerosis (MS) in 1996, and the revised descriptors in 2013, there have been calls for the development of course descriptors anchored to the biological mechanisms of the disease.1 Some conceptual models have been suggested, but as yet none have been widely adopted (Antel, Antel and Caramanos, 2012).2,3,4 Recently, the International Advisory Committee on Clinical Trials in Multiple Sclerosis (an...